Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Gamma Interferon Loaded Onto Albumin Nanoparticles: In Vitro And In Vivo Activities Against Brucella Abortus

S. Segura, C. Gamazo, J. M. Irache, S. Espuelas
Published 2007 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT The aim of this study was to evaluate the activity of gamma interferon (IFN-γ) when it was either adsorbed onto or loaded into albumin nanoparticles. Brucella abortus-infected macrophages and infected BALB/c mice were selected as the models for testing of the therapeutic potentials of these cytokine delivery systems, in view of the well-established role of IFN-γ-activated macrophages for the control of Brucella sp. infections. Whereas the encapsulation of IFN-γ inside the matrix of nanoparticles completely abrogated its activity, adsorbed IFN-γ increased by 0.75 log unit the bactericidal effect induced by RAW macrophages activated with free IFN-γ, along with a higher level of production of nitric oxide. In infected BALB/c-mice, IFN-γ adsorbed onto nanoparticles was also more active than free cytokine in reducing the number of bacteria in the spleens, and the effect was mediated by an increased ratio of IFN-γ-secreting (Th1) to interleukin-4-secreting (Th2) cells. Overall, albumin nanoparticles would be suitable as carriers that target IFN-γ to macrophages and, thus, potentiate their therapeutic activity.
This paper references
10.1002/EJI.1830250922
CD8+ Type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I‐ and class II‐deficient mice
S. C. Oliveira (1995)
10.1016/S0165-2478(97)86446-2
Expression and bactericidal activity of nitric oxide synthase in Brucella suis-infected murine macrophages.
A. Gross (1998)
Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice
E. A. Murphy (2001)
10.1310/T4R0-WBPL-Q2Q6-TU49
Interferon-gamma Therapy Activates Human Monocytes for Enhanced Phagocytosis of Mycobacterium avium Complex in HIV-Infected Individuals
K. Kedzierska (2004)
10.1093/INFDIS/167.SUPPLEMENT_1.S13
The Role of Interferon-γ in the Treatment of Visceral and Diffuse Cutaneous Leishmaniasis
R. Badaró (1993)
10.1128/IAI.61.1.124-134.1993
Effects of cytokines on intracellular growth of Brucella abortus.
X. Jiang (1993)
10.1128/IAI.63.3.1130-1133.1995
Interleukin-10 downregulates protective immunity to Brucella abortus.
D. M. Fernandes (1995)
10.1128/CMR.13.4.615-650.2000
Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?
M. Labro (2000)
10.1016/S0168-3659(01)00549-1
Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.
F. Ahsan (2002)
10.4049/jimmunol.167.3.1423
IL-12 Induction by a Th1-Inducing Adjuvant In Vivo: Dendritic Cell Subsets and Regulation by IL-10
L. Huang (2001)
10.1128/IAI.61.11.4899-4901.1993
Endogenous gamma interferon mediates resistance to Brucella abortus infection.
Y. Zhan (1993)
10.1093/JAC/DKL257
Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin.
C. Lecároz (2006)
10.1111/J.1574-695X.2001.TB00536.X
Immune control of Brucella abortus 2308 infections in BALB/c mice.
E. Murphy (2001)
10.1016/S1388-1981(00)00174-8
Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects.
M. van Slooten (2001)
Efficiency of recombinant human TNF in human cancer therapy.
F. Lejeune (2006)
10.1084/JEM.158.3.670
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity
C. Nathan (1983)
10.1128/IAI.60.10.4407-4409.1992
Effects of gamma interferon and indomethacin in preventing Brucella abortus infections in mice.
M. G. Stevens (1992)
J. Immunol
10.1016/S0378-1135(02)00222-5
Fundamentals of host immune response against Brucella abortus: what the mouse model has revealed about control of infection.
C. Baldwin (2002)
10.1023/A:1007514424253
Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines
M. van Slooten (2004)
10.1023/A:1018936522266
Interferon-γ in Starch Microparticles: Nitric Oxide-Generating Activity in Vitro and Antileishmanial Effect in Mice
L. Degling (2004)
10.1097/00001432-200006000-00006
Phagocytosis and killing of intracellular pathogens: interaction between cytokines and antibiotics.
Y. Ouadrhiri (2000)
10.1093/JAC/DKI144
Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice.
S. Prior (2005)
10.1159/000090319
Established and Emerging Therapies for the Treatment of Viral Hepatitis
D. Forton (2006)
10.1128/IAI.68.1.342-351.2000
In Vitro Brucella suis Infection Prevents the Programmed Cell Death of Human Monocytic Cells
A. Gross (2000)
10.1093/INFDIS/171.2.385
Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined.
T. L. T. ten Hagen (1995)
10.1081/DDC-52063
Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
S. Segura (2005)
Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines.
M. van Slooten (2001)
Long-term interferon-gamma therapy for patients with chronic granulomatous disease.
B. Marciano (2004)
Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose.
I. Hamada (2002)
10.1038/nri1604
Mechanisms of type-I- and type-II-interferon-mediated signalling
L. Platanias (2005)
10.1086/422993
Long-Term Interferon-γ Therapy for Patients with Chronic Granulomatous Disease
B. Marciano (2004)
Interferon-gamma therapy: evaluation of routes of administration and delivery systems.
H. Younes (2002)
10.1016/S1388-1981(01)00092-0
Immunoadjuvant activity of interferon-γ-liposomes co-administered with influenza vaccines
M. L. V. Slooten (2001)
10.1006/CIMM.1993.1241
Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide.
X. Jiang (1993)
10.1002/JPS.10007
Interferon‐γ therapy: Evaluation of routes of administration and delivery systems
H. Younes (2002)
10.1128/IAI.66.4.1309-1316.1998
Expression and Bactericidal Activity of Nitric Oxide Synthase in Brucella suis-Infected Murine Macrophages
A. Gross (1998)
10.2174/187152006776930864
Promotion of optimized protein therapy by bioconjugation as a polymeric DDS.
Y. Abe (2006)
The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis.
R. Badaró (1993)



This paper is referenced by
10.1016/j.vetimm.2011.04.004
Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel.
A. Q. Abbady (2011)
10.5772/61706
Antibiotic Susceptibility Testing of Brucella Species - Old and New Drugs
M. Maurin (2015)
10.1517/17425247.5.5.499
Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles
Guilin Wang (2008)
10.1002/btpr.12
Polyethylenimine‐coated albumin nanoparticles for BMP‐2 delivery
S. Zhang (2008)
10.1016/j.jconrel.2011.07.031
Albumin-based nanoparticles as potential controlled release drug delivery systems.
Ahmed O Elzoghby (2012)
10.2217/imt.12.26
Particle-mediated delivery of cytokines for immunotherapy.
D. Christian (2012)
10.1111/jphp.12460
Development of glutathione‐conjugated asiatic acid‐loaded bovine serum albumin nanoparticles for brain‐targeted drug delivery
N. Raval (2015)
10.1016/j.ijbiomac.2020.02.179
Protein nanocomposites: Special inferences to lysozyme based nanomaterials.
Sharanya Sarkar (2020)
10.1039/c9bm00393b
Chitosan/poly(γ-glutamic acid) nanoparticles incorporating IFN-γ for immune response modulation in the context of colorectal cancer.
Flávia Castro (2019)
10.1007/12_2012_195
Phytomedicine-Loaded Polymeric Nanomedicines: Potential Cancer Therapeutics
S. Maya (2012)
10.31548/dopovidi2018.01.005
Meaning Of Nanoparticipants In Interferon Transport
V. A. Syinycin (2018)
10.1016/j.ijpharm.2010.10.041
Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity.
Tae Hyung Kim (2011)
Chapter 9 Antibiotic Susceptibility Testing of Brucella Species-Old and New Drugs
M. Maurin (2019)
10.3389/fimmu.2018.00847
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flávia Castro (2018)
10.3390/ma11030394
Protein-Based Nanoparticle Preparation via Nanoprecipitation Method
Mohamad Tarhini (2018)
10.1007/s11095-009-9897-z
Nanoparticulate Systems for Growth Factor Delivery
S. Zhang (2009)
MECHANISMS AND REVERSAL OF ELASTIN SPECIFIC MEDIAL ARTERIAL CALCIFICATION
Y. Lei (2014)
Vaccine adjuvants : methods and protocols
G. Davies (2010)
10.1016/j.ijbiomac.2018.01.030
Biological macromolecules based targeted nanodrug delivery systems for the treatment of intracellular infections.
V. Aparna (2018)
10.1016/j.biomaterials.2009.10.011
Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery.
S. Zhang (2010)
10.31073/VET_BIOTECH32(2)-60
Modern aspects of using nanocomposites for improvement of drugs (review)
V. A. Sinitsyn (2018)
10.7150/thno.38425
Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy
Seungho Lim (2019)
10.1111/j.1574-6968.2009.01530.x
Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline.
Mohamed N. Seleem (2009)
10.1007/s11095-008-9692-2
Preparation of BMP-2 Containing Bovine Serum Albumin (BSA) Nanoparticles Stabilized by Polymer Coating
G. Wang (2008)
10.1016/j.vetpar.2011.05.028
Nanomedicine: novel approaches in human and veterinary therapeutics.
J. M. Irache (2011)
Development of Solid Lipid-polymer Hybrid Nanoparticles as Potential Oral Delivery Systems for Lipophilic Bioactive Compounds
Taoran Wang (2019)
10.1007/978-1-60761-585-9_19
Adjuvant activity of cytokines.
M. Tovey (2010)
10.1134/S0003683813070041
Studies on the physicochemical properties of the new preparation deltaferon as a component of a molecular construct
O. S. Korovina (2013)
10.1002/jps.22298
Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
T. Kim (2011)
10.1007/978-1-60761-585-9
Vaccine Adjuvants
John M. Walker (2010)
10.1021/acs.molpharmaceut.6b01074
Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.
Yi Gou (2017)
10.1021/jp5041713
Modeling the interaction of interferon α-1b to bovine serum albumin as a drug delivery system.
Q. Luo (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar